研究成果 |
主持科研项目: 1. 国家重点研发计划，2017YFC1702103，人参产业关键技术研究及大健康产品开发，2017YFC1702103，2018/01 – 2021/12，90万元，结题，子课题负责人。 2. 国家自然科学基金青年项目，81800154，新型CRM1抑制剂KPT-330协同增强ABT-199抗AML活性及机制研究， 2019/01 – 2021/12，21万元，结题，负责人 3. 吉林省科技发展计划项目，20220101284JC，下调Mcl-1和c-Myc介导的新型FLT3抑制剂MRX-2843抗FLT3突变阳性AML活性，2022/07-2025/06，10万元，在研，负责人 代表性论文： 1. Li, A.; Yu, M.; Zhao, Y.; Wu, S.; Wang, G.*; Wang, L.* Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia. Investigational new drugs 2025, 43, 301-310, doi:10.1007/s10637-025-01520-z. 2. Wang, Y.#; Lin, X.#; Wang, Y.*; Wang, G.* Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage. Investigational new drugs 2024, 42, 70-79, doi:10.1007/s10637-023-01415-x. 3. Wang, Y.; Wang, D.; Wang, Y.; Yang, H.; Wang, G.*; Wu, S.* Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia. Neoplasma 2023, 70, 287-293, doi:10.4149/neo_2023_221217N1185. 4. Liu, S.; Qiao, X.; Wu, S.; Gai, Y.; Su, Y.; Edwards, H.; Wang, Y.; Lin, H.; Taub, J.W.; Wang, G.*; Ge, Y.* c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis 2022, 27, 913-928, doi:10.1007/s10495-022-01756-7. 5. Wu, S.; Edwards, H.; Wang, D.; Liu, S.; Qiao, X.; Carter, J.; Wang, Y.; Taub, J.W.; Wang, G.*; Ge, Y.* Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells 2022, 11, doi:10.3390/cells11172752. 6. Yu, H.; Wu, S.; Liu, S.; Li, X.; Gai, Y.; Lin, H.; Wang, Y.; Edwards, H.; Ge, Y.; Wang, G.* Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. Journal of cellular and molecular medicine 2022, 26, 2646-2657, doi:10.1111/jcmm.17274. 7. Qiao, X.; Ma, J.; Knight, T.; Su, Y.; Edwards, H.; Polin, L.; Li, J.; Kushner, J.; Dzinic, S.H.; White, K.; Wang, J.; Lin, H.; Wang, Y.; Wang, L.; Wang, G.*; Taub, J.W.*; Ge, Y.* The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood cancer journal 2021, 11, 111, doi:10.1038/s41408-021-00502-7. 8. Liu, F.; Kalpage, H.A.; Wang, D.; Edwards, H.; Hüttemann, M.; Ma, J.; Su, Y.; Carter, J.; Li, X.; Polin, L.; Kushner, J.; Dzinic, S.H.; White, K.; Wang, G.*; Taub, J.W.; Ge, Y.* Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers 2020, 12, 2400, doi:10.3390/cancers12092400. 9. Zheng, H.; Zhu, T.; Li, X.; Wang, G.*; Jia, Q.* Immobilization of beta-Cyclodextrin-Conjugated Lactoferrin onto Polymer Monolith for Enrichment of Ga in Metabolic Residues of Ga-Based Anticancer Drugs. Biomacromolecules 2017, 18, 3971-3977, doi:10.1021/acs.biomac.7b01003. 10. Liu, S.; Ge, Y.; Wang, T.; Edwards, H.; Ren, Q.; Jiang, Y.; Quan, C.*; Wang, G.* Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncology reports 2017, 37, 3377-3386, doi:10.3892/or.2017.5580. |
